Creative Biolabs, Leader in Recombinant Antibody Discovery and Manufacturing

Posted by Jerry Carter on May 2nd, 2019

Creative Biolabs, founded in 2005 and headquartered in Shirley, New York, is a word-leading service supplier in recombinant antibody discovery and manufacturing. This biotechnological company has been committing itself to producing the most comprehensive list of superb recombinant antibodies. Its products range from antibody or peptide libraries, biosimilar cell lines, chimeric antigen receptor (CAR) products, antibody-drug conjugates (ADCs) to engineered antibodies (for example, therapeutic antibodies, single-domain antibodies, bispecific antibodies and intrabodies).

By adopting the hybridoma or phage display technology, Creative Biolabs has managed to optimize its library construction and screening processes, enabling the generation of Hi-Affi™ recombinant antibodies. The company has a capacity to isolate clones in a short period, with their affinity going up to the sub-nanomolar level. On top of that, it can deal with bulk orders from 1mg to 10g. The company offers a wide range of recombinant antibody products, including scFv fragment antibodies, Fab fragment antibodies, chicken IgY antibodies, rabbit monoclonal antibodies, rabbit monoclonal antibodies, rabbit monoclonal antibodies, epitope-specific antibodies, model organism antibodies, anti-idiotypic antibodies, agonistic antibodies and neuroscience antibodies, etc. Of these popular products, two will be introduced in detail.

First, the agonistic antibody. Creative Biolabs has a complete repertoire of agonistic antibodies that have been applied to antibody-based therapies. Besides the classical mechanism of actions, such as neutralization, blocking and antibody-dependent cellular cytotoxicity (ADCC), therapeutic antibodies can also act as the agonists of the receptors, basically replacing the activity of the normal ligand. The agonist activity can occur when the antibody binds the receptor in a way that resembles the binding of the physiological ligand leading to antibody-mediated agonism.

At present, many of the agonistic antibodies in clinical and pre-clinical studies target TNF family members, such as OX40, CD27, 4-1BB and DR5. More than 11 therapeutic antibodies in clinical trials tend to function as agonists, for example, the anti-CD40 antibody, CP-870893, anti-DR5 antibody, conatumumab, anti-GITR antibody, and TRX518. The company’s primary agonistic antibody products include CD27, LTBR, LTBR, FAS, DR5, CD40, OX40, TrkB, TrkC, 4-1BB, MPL, DR4, DR6, GITR, TSHR, TWEAKR, TWEAK, Tnfrsf1a, and so on.

Second, the epitope specific antibody. Creative Biolabs offers a variety of antibody products with their corresponding epitopes determined. In antibody-related research, specific epitope is always necessary for the selection of antibodies with specific binding affinity and biological functions. To prepare antibodies for various antibody-based assays and for therapeutic applications, researchers have to take into account many of the properties about the target, such as domains, conformation, similarity among species, and interaction with its counterparts. All of these properties relate to epitope to some extent. The company’s epitope-specific antibody products mainly include MUC1, APP, CD40LG, F8, ICAM1, MOG, IFNG, MLANA, Ceacam1, TP53, IGHG1, F9, PRNP, EBV LMP1, F3, C5AR1, HIV-1 Env, IL10, etc.

By the way, the company also provides high-quality custom antibody discovery and engineering services, featuring phage display library construction, antibody humanization, chimerization, engineered antibody production (Fab, scFc, tribody, bispecific antibody, SdAb, minibody, etc.), antibody labeling, hybridoma/stable cell line development, membrane protein production and cGMP-manufacturing. Importantly, Creative Biolabs is able to produce antibodies in a large scale, so as to contribute to animal-based assays and clinical trials.